Revolution Medicines (RVMD) reported a Q4 net loss late Wednesday of $1.12 per diluted share, narrowing from a loss of $1.14 a year earlier.

Analysts polled by FactSet expected a loss of $1.02

The company did not report any revenue for the quarter ended Dec. 31.

The company expects its current cash, cash equivalents and marketable securities to fund operations into the second half of 2027.

Shares of the compnay were down 2% in recent after-hours activity.